prodchem
Aug 21, 2026
The race to replace 6PPD, a critical antiozonant used in tires and rubber products, is becoming one of the most closely watched specialty-chemical reformulation efforts in the industry.
The urgency comes from 6PPD-quinone (6PPDQ), a transformation product formed when 6PPD reacts with ozone and oxygen. Research has linked 6PPDQ to acute toxicity in certain salmon species, turning what was once a standard tire additive into an environmental and regulatory concern.
For chemical manufacturers, tire companies, additive suppliers and procurement teams, the challenge is unusually complex: the replacement must reduce environmental risk without compromising tire safety, durability and performance.
6PPD has been used for decades because it performs an essential function.
It protects rubber against:
Ozone degradation
Oxygen exposure
Cracking
Weathering
Premature aging
The problem is therefore not simply finding a less-toxic chemical.
The replacement must reproduce the performance characteristics that make 6PPD essential to modern tires.
USTMA says there is currently no commercially available alternative that simultaneously provides comparable safety and performance while minimizing potential environmental effects.
The modern replacement effort accelerated after 6PPDQ's toxicity was identified in 2020.
USTMA subsequently asked California regulators to review 6PPD, and California designated motor-vehicle tires containing 6PPD as a Priority Product effective October 2023.
The industry then moved into a structured alternatives-analysis process.
This creates an unusually visible timeline:
2020 — Environmental hazard identified
2023 — California Priority Product designation
2024 — Preliminary alternatives analysis
2026 — Continued candidate testing
2029 — Final California alternatives analysis deadline
The scale of the search demonstrates how difficult the chemistry problem is.
The USTMA consortium initially identified more than 60 potential candidates.
After extensive review, seven possible alternatives were advanced for Stage 2 evaluation. The broader evaluation has since expanded as additional information and candidates have emerged.
This is not a simple one-for-one chemical substitution.
It is a full materials-reformulation exercise.
A candidate can look promising in laboratory chemistry and still fail as a commercial tire additive.
Tire manufacturers must evaluate:
Rubber durability
Ozone resistance
Mechanical properties
Aging
Environmental behavior
Toxicity
Manufacturing compatibility
Vehicle safety
USTMA estimates that development and performance testing for a tire using an existing commercially produced material can take 4 to 6.5 years, followed by at least another four years of limited-scale field testing once a suitable new antidegradant is identified.
That timeline explains why replacement cannot happen immediately.
Other specialty-chemical substitutions show that regulatory pressure does not automatically produce rapid commercial replacement.
Reformulation typically requires several stages:
Hazard identification → Candidate screening → Performance testing → Regulatory review → Field trials → Commercial deployment
For products such as tires, coatings, plastics and specialty additives, the process can become even longer because the replacement must work inside a complex formulation rather than as a standalone chemical.
One frequently cited comparison is the phaseout of ozone-depleting substances.
The Montreal Protocol established predefined reduction targets and created a clear market signal for alternatives before all replacement technologies were commercially mature.
Researchers studying tire additives have suggested a similar approach could accelerate 6PPD replacement, including a roughly 10-year phaseout framework.
The comparison is useful because it demonstrates how regulation can create demand for new chemistry before a complete replacement ecosystem exists.
A major difference is safety.
A coating or industrial additive may sometimes be reformulated with relatively limited consequences.
A tire additive directly affects:
Vehicle handling
Tire life
Crack resistance
Safety
Durability
A failed formulation could therefore create physical safety consequences.
That makes performance testing a critical bottleneck.
The search is no longer limited to academic laboratories.
In November 2025, Flexsys announced what it described as the industry's first viable 6PPD alternative, following years of research and testing.
Other chemical suppliers are also pursuing alternative chemistries.
Potential approaches include:
Alternative PPD derivatives
Non-PPD antidegradants
Triazines
Hindered phenols
Hydroquinones
Phosphites
Graphene-based materials
Bio-based antiozonants
California's DTSC currently lists multiple emerging and potential alternatives for further evaluation.
That diversification is important.
Some alternatives attempt to remain chemically close to 6PPD.
Others take a fundamentally different approach.
This creates several competing pathways:
These attempt to maintain existing tire-manufacturing processes with minimal changes.
These could potentially avoid some of the environmental concerns associated with PPD derivatives.
These introduce renewable chemistry into the tire-additive market.
Graphene and other engineered materials represent another potential route.
The winner will ultimately be determined by the combination of performance, safety, environmental profile and cost.
The regulatory focus is also broadening.
In July 2026, California finalized a regulation adding PPD derivatives to its Candidate Chemicals List, effective October 1, 2026.
This is significant because simply replacing 6PPD with another chemically similar PPD may not provide a permanent regulatory solution.
The industry may therefore need to move beyond substitution toward genuinely safer additive chemistry.
Even a technically successful alternative must remain economically viable.
Tire manufacturers will evaluate:
Raw-material costs
Production scale
Supply availability
Formulation requirements
Manufacturing changes
Testing costs
Regulatory compliance
Long-term performance
A replacement that costs substantially more than 6PPD may face adoption barriers unless regulatory requirements force the transition.
6PPD is a global specialty additive with established manufacturing and distribution networks.
Replacing it could therefore reshape demand across the chemical supply chain.
Chemical suppliers may need to develop new:
Production capacity
Feedstock relationships
Testing capabilities
Regulatory dossiers
Customer qualification programs
For traders and distributors, this could create an entirely new specialty-additive market.
Companies that wait until regulations require substitution may face limited supplier options.
Procurement teams should already be monitoring:
Alternative-additive developers
Commercial testing progress
Production capacity
Regulatory status
Toxicity data
Tire-industry qualification
Supplier concentration
Early engagement could become particularly important if one or two alternatives emerge as industry standards.
The 6PPD case combines several pressures at once:
Environmental toxicity
Regulatory action
Consumer-product exposure
Complex performance requirements
Global supply-chain dependence
This combination makes it one of the more demanding specialty-additive reformulation challenges in recent chemical-industry history.
The 6PPD replacement race is unlikely to be resolved through a single breakthrough.
Instead, the industry appears to be moving through a long qualification process involving multiple chemical families, suppliers and testing programs.
California's current framework extends the formal alternatives-analysis process through 2029, while manufacturers continue testing candidates and reporting progress.
That timeline provides a useful benchmark against historical specialty-chemical reformulations.
The key question is no longer whether the industry wants to replace 6PPD.
It is whether suppliers can deliver an alternative that is safer, commercially scalable and capable of matching the performance of a chemical that has protected tires for decades.
For chemical companies, the race represents a major specialty-additive opportunity.
For tire manufacturers, it is a long-term product-development challenge.
And for procurement teams, it could eventually transform the supplier landscape for one of the world's most widely used rubber additives.
6PPD is a critical tire antiozonant, but its transformation product 6PPDQ has raised major environmental concerns.
California designated tires containing 6PPD as a Priority Product in 2023.
More than 60 potential alternatives were initially identified, with a smaller group advancing through detailed evaluation.
Tire reformulation requires years of performance and field testing because safety and durability cannot be compromised.
USTMA estimates that development and testing alone can take multiple years before additional field validation and deployment.
Flexsys announced a viable 6PPD alternative in 2025, indicating that commercial development is accelerating.
California is broadening its regulatory focus to PPD derivatives.
The winning alternative must balance toxicity, performance, cost, scalability and regulatory acceptance.
Procurement teams should monitor alternative suppliers before regulatory deadlines force rapid substitution.
The 6PPD race could become one of the specialty chemical industry's most important additive-reformulation case studies.
Featured Product
Found this useful?
Continue Reading
The April 2026 chemical incident in Institute, West Virginia continues to draw attention from chemical safety trade associations. Its focus on decommissioning procedures and hazard review protocols offers important lessons for companies managing aging or retired chemical assets.
Khartis plans to launch its first clinical trial for an oral IGF-1R inhibitor in the first quarter of 2027. The program will advance alongside three additional preclinical immunology programs, creating new implications for pharmaceutical sourcing and development supply chains.
Khartis brings former XinThera leaders back together after Gilead’s 2023 acquisition of the company. The move highlights how experienced small-molecule research teams can become a foundation for new pharmaceutical ventures.
